Altasciences’ Ethnobridging Solutions Safely Accelerate Drug Development


Clinical data generated by ethnobridging trials in Asian populations are meant to safely accelerate development timelines by evaluating: 

  • Efficacy 
  • Safety 
  • Dosage 
  • Dosing regimen 

In Asia-Pacific countries, ethnobridging studies can reduce drug development timelines by four or five years ― the time it typically takes to complete clinical development in the region versus in North America or Europe. 

Discover how you can reduce your drug development timelines. 

Download the Fact Sheet

You may also be interested in the following:

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.